MedTrace Logo

Prevalence and Characteristics of Transthyretin Amyloidosis in Patients With Left Ventricular Hypertrophy of Unknown Etiology

NCT03842163 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 812

Last updated 2024-02-12

Study results available
· View outcomes & findings →

Summary

The main purpose of this study is to determine the prevalence of ATTR Cardiomyopathy among patients admitted due to Left Ventricular Hypertrophy (LVH) \>15mm of unknown etiology by using a 99mTc-tracer scintigraphy based protocol

Conditions

  • Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)

Interventions

DIAGNOSTIC_TEST

Diagnosis of TTR amyloidosis cardiomyopathy

Diagnosis of TTR amyloidosis cardiomyopathy with scintigraphy

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Min Age
50 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-07-09
Primary Completion
2022-06-08
Completion
2022-06-08

Countries

  • Australia
  • Austria
  • France
  • Italy
  • Portugal
  • Romania
  • Slovakia
  • Slovenia
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03842163 on ClinicalTrials.gov